Metabolic sequelae of Β-blocker therapy: Weighing in on the obesity epidemic

International Journal of Obesity

Volumn 35, Issue 11, 2011, Pages 1395-1403

  Lee, P ^a,b,c   Kengne, A P ^d   Greenfield, J R ^a,b,c   Day, R O ^a,c   Chalmers, J ^d   Ho, K K Y ^a,b,c  

^a ST VINCENT S HOSPITAL   (Australia)

^b GARVAN INSTITUTE OF MEDICAL RESEARCH   (Australia)

^c UNIVERSITY OF NEW SOUTH WALES   (Australia)

^d UNIVERSITY OF SYDNEY   (Australia)

Author keywords

blocker; brown adipose tissue; diet induced thermogenesis; energy expenditure; habitual activity

Indexed keywords

ATENOLOL; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; METOPROLOL;

ADULT; AGED; ANTHROPOMETRY; ARTICLE; BETA ADRENERGIC RECEPTOR BLOCKING; BODY MASS; BODY WEIGHT; CLINICAL ARTICLE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DIABETES MELLITUS; DIET; ENERGY EXPENDITURE; FEMALE; HUMAN; HYPERTENSION; LIPID OXIDATION; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; OUTPATIENT DEPARTMENT; PRIORITY JOURNAL; SIDE EFFECT; THERMOGENESIS; WAIST CIRCUMFERENCE; WEIGHT GAIN;

ABSORPTIOMETRY, PHOTON; ADIPOSITY; ADRENERGIC BETA-ANTAGONISTS; AGED; ANTIHYPERTENSIVE AGENTS; AUSTRALIA; BODY MASS INDEX; BODY WEIGHT; CASE-CONTROL STUDIES; ENERGY METABOLISM; FEMALE; HUMANS; HYPERTENSION; LIPID PEROXIDATION; MALE; MIDDLE AGED; OBESITY; PROSPECTIVE STUDIES; QUESTIONNAIRES; THERMOGENESIS; WAIST CIRCUMFERENCE;

EID: 81155128647     PISSN: 03070565     EISSN: 14765497     Source Type: Journal    
DOI: 10.1038/ijo.2010.284     Document Type: Article

References (51)

1. Whitlock G, Lewington S, Sherliker P, Clarke R, Emberson J, Halsey J et al. Body-mass index and cause-specific mortality in 000 adults: collaborative analyses of 57 prospective studies. Lancet 2009; 373: 1083-1096.
2. Gregg EW, Cheng YJ, Cadwell BL, Imperatore G, Williams DE, Flegal KM et al. Secular trends in cardiovascular disease risk factors according to body mass index in US adults. JAMA 2005; 293: 1868-1874. (Pubitemid 40548183)
3. Flegal KM, Carroll MD, Ogden CL, Curtin LR. Prevalence and trends in obesity among US adults, 1999-2008. JAMA 2010; 303: 235-241.
4. Zaninotto P, Head J, Stamatakis E, Wardle H, Mindell J. Trends in obesity among adults in England from 1993 to 2004 by age and social class and projections of prevalence to 2012. J Epidemiol Community Health 2009; 63: 140-146.
5. Greenfield JR, Campbell LV. Role of the autonomic nervous system and neuropeptides in the development of obesity in humans: targets for therapy? Curr Pharm Des 2008; 14: 1815-1820. (Pubitemid 351998585)
6. Bray GA. Obesity, a disorder of nutrient partitioning: the MONA LISA hypothesis. J Nutr 1991; 121: 1146-1162.
7. Bray GA. Obesity-a state of reduced sympathetic activity and normal or high adrenal activity (the autonomic and adrenal hypothesis revisited). Int J Obes 1990; 14(Suppl 3): 77-91; discussion 91-72.
8. Astrup A. The sympathetic nervous system as a target for intervention in obesity. Int J Obes Relat Metab Disord 1995; 19(Suppl 7): S24-S28. (Pubitemid 26004027)
9. Macdonald IA. Advances in our understanding of the role of the sympathetic nervous system in obesity. Int J Obes Relat Metab Disord 1995; 19(Suppl 7): S2-S7. (Pubitemid 26003010)
10. Bachman ES, Dhillon H, Zhang CY, Cinti S, Bianco AC, Kobilka BK et al. betaAR signaling required for diet-induced thermogenesis and obesity resistance. Science 2002; 297: 843-845. (Pubitemid 34839635)
11. Buemann B, Astrup A, Quaade F, Madsen J. 24-h energy expenditure and substrate oxidation rates are unaffected by body fat distribution in obese women. Metabolism 1994; 43: 109-113.
12. Acheson K, Jequier E, Wahren J. Influence of beta-adrenergic blockade on glucose-induced thermogenesis in man. J Clin Invest 1983; 72: 981-986. (Pubitemid 14212615)
13. Lamont LS, Brown T, Riebe D, Caldwell M. The major components of human energy balance during chronic beta-adrenergic blockade. J Cardiopulm Rehabil 2000; 20: 247-250. (Pubitemid 30618628)
14. Gordon NF, van Rensburg JP, van den Heever DP, Kalliatakis NB, Myburgh DP. Effect of dual beta-blockade and calcium antagonism on endurance performance. Med Sci Sports Exerc 1987; 19: 1-6. (Pubitemid 17026319)
15. Dressendorfer RH, Franklin BA, Gordon S, Timmis GC. Resting oxygen uptake in coronary artery disease. Influence of chronic beta-blockade. Chest 1993; 104: 1269-1272.
16. Steinkraus V, Nose M, Scholz H, Thormahlen K. Time course and extent of alpha 1-adrenoceptor density changes in rat heart after beta-adrenoceptor blockade. Br J Pharmacol 1989; 96: 441-449. (Pubitemid 19045121)
17. Study rationale and design of ADVANCE: action in diabetes and vascular disease-preterax and diamicron MR controlled evaluation. Diabetologia 2001; 44: 1118-1120.
18. Merlo J, Wessling A, Melander A. Comparison of dose standard units for drug utilisation studies. Eur J Clin Pharmacol 1996; 50: 27-30. (Pubitemid 26141504)
19. O'Sullivan AJ, Crampton LJ, Freund J, Ho KK. The route of estrogen replacement therapy confers divergent effects on substrate oxidation and body composition in postmenopausal women. J Clin Invest 1998; 102: 1035-1040. (Pubitemid 28419248)
20. Frayn KN. Calculation of substrate oxidation rates in vivo from gaseous exchange. J Appl Physiol 1983; 55: 628-634. (Pubitemid 13044099)
21. Ferrannini E. The theoretical bases of indirect calorimetry: a review. Metabolism 1988; 37: 287-301. (Pubitemid 18080935)
22. Greenfield JR, Samaras K, Hayward CS, Chisholm DJ, Campbell LV. Beneficial postprandial effect of a small amount of alcohol on diabetes and cardiovascular risk factors: modification by insulin resistance. J Clin Endocrinol Metab 2005; 90: 661-672. (Pubitemid 40279177)
23. O'Sullivan AJ, Kelly JJ, Hoffman DM, Freund J, Ho KK. Body composition and energy expenditure in acromegaly. J Clin Endocrinol Metab 1994; 78: 381-386. (Pubitemid 24061757)
24. Carey DG, Jenkins AB, Campbell LV, Freund J, Chisholm DJ. Abdominal fat and insulin resistance in normal and overweight women: direct measurements reveal a strong relationship in subjects at both low and high risk of NIDDM. Diabetes 1996; 45: 633-638. (Pubitemid 26140548)
25. Richardson MT, Ainsworth BE, Jacobs DR, Leon AS. Validation of the Stanford 7-day recall to assess habitual physical activity. Ann Epidemiol 2001; 11: 145-153. (Pubitemid 32054781)
26. Rowe DA, Kemble CD, Robinson TS, Mahar MT. Daily walking in older adults: day-to-day variability and criterion-referenced validity of total daily step counts. J Phys Act Health 2007; 4: 434-446.
27. Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008; 358: 2560-2572. (Pubitemid 351831357)
28. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of The National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high Blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001; 285: 2486-2497.
29. Cannon B, Nedergaard J. Brown adipose tissue: function and physiological significance. Physiol Rev 2004; 84: 277-359. (Pubitemid 38054374)
30. Lee P, Greenfield JR, Ho KK, Fulham MJ. A critical appraisal of prevalence and metabolic significance of brown adipose tissue in adult humans. Am J Physiol Endocrinol Metab 2010; 299: E601-E606.
31. Soderlund V, Larsson SA, Jacobsson H. Reduction of FDG uptake in brown adipose tissue in clinical patients by a single dose of propranolol. Eur J Nucl Med Mol Imaging 2007; 34: 1018-1022. (Pubitemid 46919548)
32. Sharma AM, Pischon T, Hardt S, Kunz I, Luft FC. Hypothesis: Beta-adrenergic receptor blockers and weight gain: A systematic analysis. Hypertension 2001; 37: 250-254. (Pubitemid 32199083)
33. Leslie WS, Hankey CR, Lean ME. Weight gain as an adverse effect of some commonly prescribed drugs: a systematic review. QJM 2007; 100: 395-404. (Pubitemid 47062891)
34. Rossner S, Taylor CL, Byington RP, Furberg CD. Long term propranolol treatment and changes in body weight after myocardial infarction. BMJ 1990; 300: 902-903. (Pubitemid 20145787)
35. Hypertension in Diabetes Study. III. Prospective study of therapy of hypertension in type 2 diabetic patients: efficacy of ACE inhibition and beta-blockade. Diabet Med 1994; 11: 773-782.
36. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. UK Prospective Diabetes Study Group. BMJ 1998; 317: 713-720.
37. Schiffrin EL. Correction of remodeling and function of small arteries in human hypertension by cilazapril, an angiotensin Iconverting enzyme inhibitor. J Cardiovasc Pharmacol 1996; 27 (Suppl 2): S13-S18. (Pubitemid 26134257)
38. Foss OP, Jensen EK. The effect of captopril and metoprolol as monotherapy or combined with bendroflumethiazide on blood lipids. J Intern Med 1990; 227: 119-123. (Pubitemid 20038882)
39. Houston MC, Olafsson L, Burger MC. Effects of nifedipine GITS and atenolol monotherapy on serum lipids, blood pressure, heart rate, and weight in mild to moderate hypertension. Angiology 1991; 42: 681-690.
40. Wikstrand J, Warnold I, Olsson G, Tuomilehto J, Elmfeldt D, Berglund G. Primary prevention with metoprolol in patients with hypertension. Mortality results from the MAPHY study. JAMA 1988; 259: 1976-1982. (Pubitemid 18082489)
41. Wilhelmsen L, Berglund G, Elmfeldt D, Fitzsimons T, Holzgreve H, Hosie J et al. Beta-blockers versus diuretics in hypertensive men: main results from the HAPPHY trial. J Hypertens 1987; 5: 561-572.
42. Centers for Disease Control and Prevention (CDC). Trends in intake of energy and macronutrients-United States, 1971-2000. MMWR Morb Mortal Wkly Rep 2004; 53: 80-82.
43. Brownson RC, Boehmer TK, Luke DA. Declining rates of physical activity in the United States: what are the contributors? Annu Rev Public Health 2005; 26: 421-443. (Pubitemid 40547391)
44. Cameron AJ, Welborn TA, Zimmet PZ, Dunstan DW, Owen N, Salmon J et al. Overweight and obesity in Australia: the 1999-2000 Australian Diabetes, Obesity and Lifestyle Study (AusDiab). Med J Aust 2003; 178: 427-432. (Pubitemid 36591915)
45. Flegal KM, Carroll MD, Kuczmarski RJ, Johnson CL. Overweight and obesity in the United States: prevalence and trends, 1960-1994. Int J Obes Relat Metab Disord 1998; 22: 39-47. (Pubitemid 28036587)
46. Ainsworth BE, Haskell WL, Whitt MC, Irwin ML, Swartz AM, Strath SJ et al. Compendium of physical activities: an update of activity codes and MET intensities. Med Sci Sports Exerc 2000; 32: S498-S504.
47. Lafontan M, Moro C, Berlan M, Crampes F, Sengenes C, Galitzky J. Control of lipolysis by natriuretic peptides and cyclic GMP. Trends Endocrinol Metab 2008; 19: 130-137. (Pubitemid 351608304)
48. Arner P, Kriegholm E, Engfeldt P, Bolinder J. Adrenergic regulation of lipolysis in situ at rest and during exercise. J Clin Invest 1990; 85: 893-898. (Pubitemid 20087493)
49. The treatment of mild hypertension study. A randomized, placebocontrolled trial of a nutritional-hygienic regimen along with various drug monotherapies. The treatment of mild hypertension research group. Arch Intern Med 1991; 151: 1413-1423.
50. Davis BR, Oberman A, Blaufox MD, Wassertheil-Smoller S, Hawkins CM, Cutler JA et al. Effect of antihypertensive therapy on weight loss. The trial of antihypertensive interventions and management research group. Hypertension 1992; 19: 393-399.
51. Jequier E, Tappy L. Regulation of body weight in humans. Physiol Rev 1999; 79: 451-480. (Pubitemid 29210928)